Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TYRA vs AURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AURA Captures Overall Composite Edge (28.8 SELL vs 32.4 SELL), While TYRA Leads 3–1 on Growth & Valuation Pillars

AURA Overall Winner 6-Pillar Tally: TYRA 3 – 1 AURA (2 Tie) Matrix Metrics: TYRA 4 – 1 AURA

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) captures the overall head-to-head institutional edge over Tyra Biosciences, Inc. (TYRA) on higher Unified Composite conviction (28.8/100 SELL vs. 32.4/100 SELL) after splitting the core matrix 1–4 (led by Options & Positioning), while TYRA wins 3–1 across the 6-pillar growth and valuation breakdown. TYRA trades at $19.77 (N/M Forward P/E, 0.0% operating margin) versus AURA at $7.21 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While TYRA currently prints a higher short-term Unified Composite Score (32.4/100 SELL vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (1–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although AURA compares more favorably head-to-head, both TYRA (32.4/100 SELL) and AURA (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: TYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TYRA vs AURA
TYRA NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.77
-1.27% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.79β · 49% Vol
Unified Composite Score
32.4 / 100 SELL
Tech 25.0 Fund 46.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $20.94 · SMA50: $21.57
AURA NASDAQ Head-to-Head Winner
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.7 · SMA20: $6.66 · SMA50: $6.54

6-Pillar Scorecard Institutional Category Breakdown (TYRA 3 – 1 AURA)

Columns: Metric · TYRA · AURA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TYRA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.3B $728.6M
3. Profitability & Quality TYRA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -34.9% -61.7%
4. Balance Sheet & Cash Flow TYRA
Cash Generation (TTM) -$120M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $451M Net Cash $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 69.0% (3rd %ile) 160.1% (22nd %ile)
Put/Call OI Skew 12.00x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TYRA (4) vs AURA (1)
Institutional Metric TYRA AURA Criterion Row Edge
Market Capitalization
Scale
$1.3B $728.6M Larger Scale TYRA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-34.9% -61.7% Higher ROE TYRA
52-Week Range Position
Momentum
20% ($15–$41) 52% ($5–$10) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.79β · 49% Vol 0.92β · 75% Vol Lower Realized Risk TYRA
Unified Institutional Score
Composite Signal
32.4 / 100 (SELL) 28.8 / 100 (SELL) Higher Composite TYRA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$120M ($451M Net Cash) -$110M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +11.45 pp
TYRA: +6.75% · AURA: +18.2%
3M Horizon AURA +12.44 pp
TYRA: -24.08% · AURA: -11.64%
6M Horizon AURA +41.08 pp
TYRA: -44.56% · AURA: -3.48%
1Y Horizon AURA +3.57 pp
TYRA: +26.81% · AURA: +30.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TYRA vs AURA. Trailing 12-month operating profitability (TYRA 0.0% vs AURA 0.0%) and valuation multiples (TYRA N/M vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TYRA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.9% · N/M
AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TYRA BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 69.0%
IV Percentile 3rd %ile
Put/Call OI Skew 12.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TYRA vs AURA Key Questions & Quantitative Answers

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) captures the overall head-to-head institutional edge over Tyra Biosciences, Inc. (TYRA) on higher Unified Composite conviction (28.8/100 SELL vs. 32.4/100 SELL) after splitting the core matrix 1–4 (led by Options & Positioning), while TYRA wins 3–1 across the 6-pillar growth and valuation breakdown. TYRA trades at $19.77 (N/M Forward P/E, 0.0% operating margin) versus AURA at $7.21 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While TYRA currently prints a higher short-term Unified Composite Score (32.4/100 SELL vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (1–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although AURA compares more favorably head-to-head, both TYRA (32.4/100 SELL) and AURA (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TYRA leads the Growth & Scale pillar: TYRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TYRA generates N/A in USD-normalized revenue versus N/A for AURA. In operating R&D and SG&A reinvestment, TYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AURA.

TYRA and AURA trade at balanced relative valuation multiples. TYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TYRA (-34.9% ROE) versus AURA (-61.7% ROE) capital efficiency.

In options market volatility and institutional positioning, TYRA carries 69.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 12.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.79β · 49% Vol realized risk). By comparison, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.